[Federal Register: November 18, 1999 (Volume 64, Number 222)]
[Notices]               
[Page 63050-63051]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr18no99-62]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

 
Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.


[[Page 63051]]


ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Methods of Inhibiting Cancer Cells With ADNF III Antisense 
Oligonucleotides

I Gozes, R Zamostiano, E Gelber, A Pinhasov, M Bassan (all of Tel Aviv 
University), DE Brenneman (NICHD)
Serial No.: 09/364,609 filed 30 Jul 1999.
Licensing Contact: Susan S. Rucker; 301/496-7056 ext. 245; e-mail: 
sr156v@nih.gov.
    This application describes methods of inhibiting the proliferation 
of cells using an antisense oligonucleotide derived from the 
polypeptide Activity Dependent Neurotrophic Factor III (ADNF III)/
Activity Dependent Neuroprotective Protein (ADNP). Preferred antisense 
oligonucleotides are complementary to the 5' region of ADNF III/ADNP. 
The ability of such antisense oligonucleotides to inhibit cell 
proliferation has been demonstrated in in vitro models such as the HT29 
colon cancer cell line. Based on the location of ADNF III/ADNP on 
chromosome 20 at 20q13, a region which has been shown via CGH to be 
associated with breast, ovary, colon, head and neck, brain and 
pancreatic cancers, ADNF III/ADNP antisense molecules might also be 
expected to be useful in treating one or more of these cancers.

Orally Active Peptides That Prevent Cell Damage and Death

DE Brenneman, CY Spong (both of NICHD), I Gozes, A Pinhasov, E Giladi 
(all of Tel Aviv University)
Serial No.: 60/149,956 filed 18 Aug. 1999.
Licensing Contact: Susan S. Rucker; 301/496-7056 ext. 245; e-mail: 
sr156v@nih.gov.
    This application describes two peptides which are orally active and 
which have been shown in in vitro assays to protect against neuronal 
cell death. In animal model systems for Alzheimer's disease and Fetal 
Alcohol Syndrome the peptide have also been demonstrated to be useful. 
The first peptide is D-SAL, a D-isomer of the peptide SAL (SALLRSIPA) 
derived from Activity Dependent Neurotrophic Factor I (ADNF I). The 
second peptide is D-NAP, a D-isomer of the peptide NAP (NAPVSIPQ) 
derived from a related protein Activity Dependent Neuroprotective 
Protein (ADNP)/Activity Dependent Neurotrophic Factor III (ADNF III). 
The peptides may be used alone or in combination. The peptides may be 
constructed solely of D-isomers of their amino acids or combinations of 
D and L amino acids. Other diseases involving neuronal cell death where 
D-SAL or D-NAP may be useful include Huntington's disease, epilepsy, 
Parkinson's disease and Tourette's syndrome.

    Dated: November 9, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 99-30067 Filed 11-17-99; 8:45 am]
BILLING CODE 4140-01-P